Technical Analysis for AKTX - Akari Therapeutics Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -0.45% | |
| 180 Bearish Setup | Bearish Swing Setup | -0.45% | |
| Outside Day | Range Expansion | -0.45% | |
| Oversold Stochastic | Weakness | -0.45% | |
| Calm After Storm | Range Contraction | -3.04% | |
| NR7 | Range Contraction | -3.04% |
| Alert | Time |
|---|---|
| Possible NR7 | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 12 hours ago |
| 20 DMA Resistance | about 12 hours ago |
| 2x Volume Pace | about 13 hours ago |
| 1.5x Volume Pace | about 13 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 09/30/2024
Akari Therapeutics Plc Description
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Organ Systems Rare Diseases Inflammatory Diseases Autoimmunity Autoimmune And Inflammatory Disease Complement System Myasthenia Gravis Myasthenia Acquired Hemolytic Anemia Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria C5a Hemolytic Uremic Syndrome Sjögren's Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.4 |
| 52 Week Low | 1.0775 |
| Average Volume | 15,796 |
| 200-Day Moving Average | 2.56 |
| 50-Day Moving Average | 2.76 |
| 20-Day Moving Average | 2.35 |
| 10-Day Moving Average | 2.39 |
| Average True Range | 0.27 |
| RSI (14) | 39.39 |
| ADX | 16.27 |
| +DI | 21.54 |
| -DI | 12.87 |
| Chandelier Exit (Long, 3 ATRs) | 2.33 |
| Chandelier Exit (Short, 3 ATRs) | 2.92 |
| Upper Bollinger Bands | 2.63 |
| Lower Bollinger Band | 2.07 |
| Percent B (%b) | 0.29 |
| BandWidth | 24.06 |
| MACD Line | -0.12 |
| MACD Signal Line | -0.13 |
| MACD Histogram | 0.0096 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.49 | ||||
| Resistance 3 (R3) | 2.51 | 2.46 | 2.44 | ||
| Resistance 2 (R2) | 2.46 | 2.39 | 2.44 | 2.43 | |
| Resistance 1 (R1) | 2.34 | 2.35 | 2.32 | 2.32 | 2.41 |
| Pivot Point | 2.29 | 2.29 | 2.27 | 2.27 | 2.29 |
| Support 1 (S1) | 2.17 | 2.22 | 2.15 | 2.15 | 2.05 |
| Support 2 (S2) | 2.12 | 2.18 | 2.10 | 2.03 | |
| Support 3 (S3) | 2.00 | 2.12 | 2.02 | ||
| Support 4 (S4) | 1.98 |
